139 citations,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
27 citations,
September 2017 in “Archives of Dermatological Research” Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
20 citations,
December 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.
17 citations,
April 2020 in “Dermatology and Therapy” The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.
11 citations,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
9 citations,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
8 citations,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
3 citations,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
November 2017 in “Asian journal of pharmaceutical and clinical research” Three compounds from Dadap leaves may help treat hair loss.
July 2017 in “British Journal of Dermatology” The document concludes that scalp conditions have various causes and can present in many different ways.
11 citations,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
185 citations,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
148 citations,
December 2018 in “Journal of autoimmunity” Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
49 citations,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
47 citations,
October 2014 in “Expert Opinion on Emerging Drugs” New alopecia treatments aim for better results and fewer side effects.
44 citations,
September 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
42 citations,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
39 citations,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
37 citations,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
32 citations,
December 2018 in “Cytokine” Type I interferons play a key role in the development of various skin diseases.
26 citations,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
25 citations,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
23 citations,
September 2019 in “Journal of The American Academy of Dermatology” Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
17 citations,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
16 citations,
July 2020 in “International Journal of Molecular Sciences” Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
15 citations,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
14 citations,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
11 citations,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
11 citations,
November 2018 in “Journal of the American Academy of Dermatology” Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.